help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Veldhuis, J. D.
Right arrow Articles by Keenan, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Veldhuis, J. D.
Right arrow Articles by Keenan, D. M.
The Journal of Clinical Endocrinology & Metabolism Vol. 89, No. 3 1312-1318
Copyright © 2004 by The Endocrine Society

Estradiol Supplementation Modulates Growth Hormone (GH) Secretory-Burst Waveform and Recombinant Human Insulin-Like Growth Factor-I-Enforced Suppression of Endogenously Driven GH Release in Postmenopausal Women

Johannes D. Veldhuis, Stacey M. Anderson, Petra Kok, Ali Iranmanesh, Jan Frystyk, Hans Ørskov and Daniel M. Keenan

Division of Endocrinology and Metabolism (J.D.V.), Department of Internal Medicine, Mayo Medical and Graduate Schools of Medicine, General Clinical Research Center, Mayo Clinic, Rochester, Minnesota 55905; Division of Endocrinology (S.M.A.), Department of Internal Medicine, General Clinical Research Center, Department of Statistics (D.M.K.), University of Virginia, Charlottesville, Virginia 22908; Department of Internal Medicine (P.K.), Leiden University Medical Center, Leiden, The Netherlands; Endocrine Service (A.I.), Medical Section, Salem Veterans Affairs Medical Center, Salem, Virginia 24153; and Institute of Experimental Clinical Research (J.F., H.Ø.), Medical Research Laboratory, Aarhus University Hospital, Aarhus, Denmark DK-8000

Address all correspondence and requests for reprints to: J. D. Veldhuis, Division of Endocrinology and Metabolism, Department of Internal Medicine, Mayo Medical and Graduate Schools of Medicine, General Clinical Research Center, Mayo Clinic, Rochester, Minnesota 55905. E-mail: veldhuis.johannes{at}mayo.edu.

The present study tests the mechanistic postulate that estrogen confers resistance to negative feedback by systemic IGF-I. To this end, eight postmenopausal women received a constant iv infusion of recombinant human (rh)IGF-I (10 µg/kg·h x 6 h) and saline in randomized order on the 10th day of supplementation with oral estradiol (E2) and placebo (Pl). GH secretion was quantitated by 10-min blood sampling, immunochemiluminometry assay, and deconvolution analysis. Administration of E2 compared with Pl followed by saline infusion: 1) stimulated pulsatile GH secretion (µg/liter·6 h), viz., 12 ± 3.3 (Pl) and 18 ± 4.6 (E2) (mean ± SEM, paired comparison, P < 0.05); 2) halved the time latency (min) to achieve peak GH secretion after GHRH injection, 24 ± 2.2 (Pl) and 12 ± 2.1 (E2) (P < 0.01); and 3) did not alter the mass of GH secreted (µg/liter) in response to a maximally effective dose of GHRH, 30 ± 7.2 (Pl) and 37 ± 11 (E2). Exposure to E2 compared with Pl followed by rhIGF-I infusion: 1) accelerated the rate of decline of GH concentrations by 3.3-fold, viz., absolute slope (µg/liter·1000 min), 3.8 (range, 2.5–5.0) (Pl) and 12 (range, 10–14) (E2) (P < 0.001); 2) augmented the algebraic decrement in GH concentrations (µg/liter) enforced by rhIGF-I infusion, 0.73 ± 0.21 (Pl) and 1.6 ± 0.25 (E2) (P < 0.01); 3) halved the time delay (min) to peak GHRH-induced GH secretion, 20 ± 1.2 (Pl) vs. 10 ± 1.3 (E2) min (P < 0.01). In contradistinction, E2 did not alter: 1) the capability of rhIGF-I to suppress GHRH-stimulated GH secretory burst mass significantly, viz., by 50 ± 8% (Pl) and 52 ± 14% (E2) (P < 0.05 each vs. saline); 2) the hourly rate of rise of infused (total) IGF-I concentrations; and 3) total and ultrafiltratably free IGF-I concentrations (µg/liter) attained at the end of the two rhIGF-I infusions.

In summary, compared with Pl, E2 supplementation in postmenopausal women: 1) amplifies endogenously driven GH secretory-burst mass; 2) initiates rapid onset of GHRH-stimulated GH release; and 3) potentiates IGF-I-dependent suppression of unstimulated GH concentrations. Based upon companion modeling data, we postulate that E2 facilitates the upstroke and IGF-I enforces the downstroke of high-amplitude GH secretory bursts in estrogen-replete individuals.

This work was supported, in part, by Grants MO1 RR00847, a Clinical Associate Physician Award, and RR00585 to the GCRCs of the University of Virginia and Mayo Clinic and Foundation from the National Center for Research Resources (Rockville, MD); R01 NIA AG 14799 and K01 NIA AG 19164 from the National Institutes of Health (Bethesda, MD); and the Hørslev Foundation, Danish Health Research Council (Grant 22020141) and Aarhus University-Novo Nordisk Center for Research in Growth and Regeneration.

Abbreviations: CI, Confidence interval; CV, coefficient of variation; E2, estradiol; GCRC, General Clinical Research Center; Pl, placebo; PRL, prolactin; rh, recombinant human.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
J. D. Veldhuis, D. M. Keenan, J. N. Bailey, A. Adeniji, J. M. Miles, R. Paulo, M. Cosma, and C. Soares-Welch
Estradiol Supplementation in Postmenopausal Women Attenuates Suppression of Pulsatile Growth Hormone Secretion by Recombinant Human Insulin-like Growth Factor Type I
J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4471 - 4478.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Cosma, J. Bailey, J. M. Miles, C. Y. Bowers, and J. D. Veldhuis
Pituitary and/or Peripheral Estrogen-Receptor {alpha} Regulates Follicle-Stimulating Hormone Secretion, Whereas Central Estrogenic Pathways Direct Growth Hormone and Prolactin Secretion in Postmenopausal Women
J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 951 - 958.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
A. A van der Klaauw, N. R Biermasz, P. M J Zelissen, A. M Pereira, E. G W M Lentjes, J. W A Smit, S. W van Thiel, J. A Romijn, and F. Roelfsema
Administration route-dependent effects of estrogens on IGF-I levels during fixed GH replacement in women with hypopituitarism
Eur. J. Endocrinol., December 1, 2007; 157(6): 709 - 716.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. D. Veldhuis, D. M. Keenan, A. Iranmanesh, K. Mielke, J. M. Miles, and C. Y. Bowers
Estradiol Potentiates Ghrelin-Stimulated Pulsatile Growth Hormone Secretion in Postmenopausal Women
J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3559 - 3565.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, and C. Y. Bowers
Somatotropic and Gonadotropic Axes Linkages in Infancy, Childhood, and the Puberty-Adult Transition
Endocr. Rev., April 1, 2006; 27(2): 101 - 140.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
D. Fintini, M. Alba, and R. Salvatori
Influence of Estrogen Administration on the Growth Response to Growth Hormone (GH) in GH-Deficient Mice
Experimental Biology and Medicine, November 1, 2005; 230(10): 715 - 720.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. D. Veldhuis, D. Erickson, K. Mielke, L. S. Farhy, D. M. Keenan, and C. Y. Bowers
Distinctive Inhibitory Mechanisms of Age and Relative Visceral Adiposity on Growth Hormone Secretion in Pre- and Postmenopausal Women Studied under a Hypogonadal Clamp
J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6006 - 6013.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
J A Kanaley, I Giannopoulou, S Collier, R Ploutz-Snyder, and R Carhart Jr
Hormone-replacement therapy use, but not race, impacts the resting and exercise-induced GH response in postmenopausal women
Eur. J. Endocrinol., October 1, 2005; 153(4): 527 - 533.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
J. D Veldhuis, D. M Keenan, K. Mielke, J. M Miles, and C. Y Bowers
Testosterone supplementation in healthy older men drives GH and IGF-I secretion without potentiating peptidyl secretagogue efficacy
Eur. J. Endocrinol., October 1, 2005; 153(4): 577 - 586.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
K. Stokes, M. Nevill, J. Frystyk, H. Lakomy, and G. Hall
Human growth hormone responses to repeated bouts of sprint exercise with different recovery periods between bouts
J Appl Physiol, October 1, 2005; 99(4): 1254 - 1261.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. D. Veldhuis, J. Frystyk, A. Iranmanesh, and H. Orskov
Testosterone and Estradiol Regulate Free Insulin-Like Growth Factor I (IGF-I), IGF Binding Protein 1 (IGFBP-1), and Dimeric IGF-I/IGFBP-1 Concentrations
J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2941 - 2947.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. D. Veldhuis, S. M. Anderson, A. Iranmanesh, and C. Y. Bowers
Testosterone Blunts Feedback Inhibition of Growth Hormone Secretion by Experimentally Elevated Insulin-Like Growth Factor-I Concentrations
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1613 - 1617.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
D. Erickson, D. M. Keenan, L. Farhy, K. Mielke, C. Y. Bowers, and J. D. Veldhuis
Determinants of Dual Secretagogue Drive of Burst-Like Growth Hormone Secretion in Premenopausal Women Studied under a Selective Estradiol Clamp
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1741 - 1751.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, A. D. Rogol, J. C. Lovejoy, M. Sheffield-Moore, N. Mauras, and C. Y. Bowers
Endocrine Control of Body Composition in Infancy, Childhood, and Puberty
Endocr. Rev., February 1, 2005; 26(1): 114 - 146.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J.-W. Chen, K. Hojlund, H. Beck-Nielsen, J. Sandahl Christiansen, H. Orskov, and J. Frystyk
Free Rather than Total Circulating Insulin-Like Growth Factor-I Determines the Feedback on Growth Hormone Release in Normal Subjects
J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 366 - 371.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. D. Veldhuis, J. Y. Weltman, A. L. Weltman, A. Iranmanesh, E. E. Muller, and C. Y. Bowers
Age and Secretagogue Type Jointly Determine Dynamic Growth Hormone Responses to Exogenous Insulin-Like Growth Factor-Negative Feedback in Healthy Men
J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5542 - 5548.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
D. Erickson, D. M. Keenan, K. Mielke, K. Bradford, C. Y. Bowers, J. M. Miles, and J. D. Veldhuis
Dual Secretagogue Drive of Burst-Like Growth Hormone Secretion in Postmenopausal Compared with Premenopausal Women Studied under an Experimental Estradiol Clamp
J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4746 - 4754.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society